

# Matthew D Howell

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7825635/publications.pdf>

Version: 2024-02-01

18  
papers

920  
citations

471371

17  
h-index

839398

18  
g-index

18  
all docs

18  
docs citations

18  
times ranked

1369  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diverse role of survival motor neuron protein. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2017, 1860, 299-315.	0.9	210
2	Gender-Specific Amelioration of SMA Phenotype upon Disruption of a Deep Intronic Structure by an Oligonucleotide. <i>Molecular Therapy</i> , 2017, 25, 1328-1341.	3.7	25
3	Activation of a cryptic 5â€² splice site reverses the impact of pathogenic splice site mutations in the spinal muscular atrophy gene. <i>Nucleic Acids Research</i> , 2017, 45, 12214-12240.	6.5	25
4	TIA1 is a gender-specific disease modifier of a mild mouse model of spinal muscular atrophy. <i>Scientific Reports</i> , 2017, 7, 7183.	1.6	23
5	Severe impairment of male reproductive organ development in a low SMN expressing mouse model of spinal muscular atrophy. <i>Scientific Reports</i> , 2016, 6, 20193.	1.6	50
6	Hippocampal administration of chondroitinase ABC increases plaque-adjacent synaptic marker and diminishes amyloid burden in aged APP <sup>swe</sup> /PS1 <sup>dE9</sup> mice. <i>Acta Neuropathologica Communications</i> , 2015, 3, 54.	2.4	38
7	ADAMTS expression and function in central nervous system injury and disorders. <i>Matrix Biology</i> , 2015, 44-46, 70-76.	1.5	73
8	A Short Antisense Oligonucleotide Ameliorates Symptoms of Severe Mouse Models of Spinal Muscular Atrophy. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e174.	2.3	47
9	Advances in therapeutic development for spinal muscular atrophy. <i>Future Medicinal Chemistry</i> , 2014, 6, 1081-1099.	1.1	43
10	Advances in therapeutic development for spinal muscular atrophy. <i>Future Medicinal Chemistry</i> , 2014, 6, 1081-1099.	1.1	21
11	Antisense oligonucleotide mediated therapy of spinal muscular atrophy. <i>Translational Neuroscience</i> , 2013, 4, 1-7.	0.7	53
12	Spinal muscular atrophy: An update on therapeutic progress. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 2180-2190.	1.8	62
13	Canonical Transient Receptor Channel 5 (TRPC5) and TRPC1/4 Contribute to Seizure and Excitotoxicity by Distinct Cellular Mechanisms. <i>Molecular Pharmacology</i> , 2013, 83, 429-438.	1.0	113
14	Altered Synaptic Marker Abundance in the Hippocampal Stratum Oriens of Ts65Dn Mice is Associated with Exuberant Expression of Versican. <i>ASN Neuro</i> , 2012, 4, AN20110037.	1.5	10
15	Lectican proteoglycans, their cleaving metalloproteinases, and plasticity in the central nervous system extracellular microenvironment. <i>Neuroscience</i> , 2012, 217, 6-18.	1.1	52
16	Selective Decline of Synaptic Protein Levels in the Frontal Cortex of Female Mice Deficient in the Extracellular Metalloproteinase ADAMTS1. <i>PLoS ONE</i> , 2012, 7, e47226.	1.1	20
17	Panel of synaptic protein ELISAs for evaluating neurological phenotype. <i>Experimental Brain Research</i> , 2010, 201, 885-893.	0.7	22
18	Abnormal post-translational and extracellular processing of brevicin in plaque-bearing mice overexpressing APP <sup>sw</sup> . <i>Journal of Neurochemistry</i> , 2010, 113, 784-795.	2.1	33